



First World Congress of Cutaneous Lymphomas

Thursday, September 23, 2010

Cutaneous T-Cell Lymphomas: Pathomechanisms

7:15 a.m. – 8:15 a.m.	Registration Check-in Breakfast
8:15 a.m. – 8:30 a.m.	Welcome: <i>Gary Wood, MD, President, ISCL</i>
Session 1: Lymphomagenesis, Epidermology, Genomics, Epigenomics, Gene Expression	
PART 1: Epidemiology, prognosis, and clinical outcomes Session Chairs: Eric Vonderheid, MD / Maarten Vermeer, MD, PhD / Youn Kim, MD / Madeleine Duvic, MD	
8:30 a.m. – 8:45 a.m.	<i>Epidemiology, trends and incidence of cutaneous lymphomas: Martin Weinstock, MD, PhD</i>
8:45 a.m. – 8:55 a.m.	Presenting Author: Rakshandra Talpur, MD; Abstract #35 LONG-TERM OUTCOMES OF 1263 PATIENTS WITH MYCOSIS FUNGOIDES AND SÉZARY SYNDROME FROM 1982-2009 <i>Talpur R¹, Daulat S¹, Seyfer S¹, Liu P², Duvic M¹, Departments of Dermatology¹ and Biostatistics,² University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA</i>
8:55 a.m. – 9:05 a.m.	Presenting Author: Wei Ai, MD, PhD; Abstract #13 INCREASED RISK OF SECOND MALIGNANCIES IN PATIENTS WITH MYCOSIS FUNGOIDES DIAGNOSED BEFORE 30 YEARS OF AGE: A POPULATION-BASED STUDY <i>Ai-WZ¹, Keegan-T², Fish-K², Pincus-L¹, Soon-C¹, Kim-Y³, Chang-E²,¹ University of California, San Francisco, San Francisco, California, USA,² Cancer Prevention Institute of California, Fremont, California, USA,² Stanford University School of Medicine, Stanford, California, USA</i>
9:05 a.m. – 9:15 a.m.	Presenting Author: Emilia Hodak, MD; Abstract #15 ASSOCIATED CO-MORBIDITIES IN PATIENTS WITH MYCOSIS FUNGOIDES <i>Hodak E¹, Lessin S², Friedland R¹, David M¹, Cohen AD³,¹ Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Tel Aviv University, Tel Aviv,³ Clalit Health Services and Sial Research Center, Ben Gurion University of the Negev, Beer Sheva, Israel, and² Fox Chase Cancer Center, Philadelphia, PA, USA</i>
9:15 a.m. – 9:25 a.m.	Presenting Author: Pietro Quaglino, MD; Abstract #18 CLONAL HETEROGENEITY IN MYCOSIS FUNGOIDES/SEZARY SYNDROME: INCIDENCE, RELATION WITH CLINICO-PATHOLOGIC FEATURES AND PROGNOSTIC SIGNIFICANCE <i>Fierro-MT, Ponti-R, Titli-S, Fava-P, Novelli-M, Quaglino-P, Bernengo-MG, Department of Biomedical Sciences and Human Oncology, Dermatologic Clinic, University of Turin, Italy</i>
9:25 a.m. – 9:35 a.m.	Presenting Author: Bridget Perrin, BS; Abstract #33 PREDICTORS OF BLOOD INVOLVEMENT IN STAGE 1A MYCOSIS FUNGOIDES PATIENTS <i>Perrin B, Morrissey K, Vittorio CC, Rook AH, Kim EJ,^{1,2} Department of Dermatology, University of Pennsylvania School of Medicine, and Hospital of the University of Pennsylvania, Philadelphia, PA, USA</i>
9:35 a.m. – 9:45 a.m.	Discussion/Questions: Youn Kim, MD (facilitator), Eric Vonderheid, MD, Maarten Vermeer, MD, PhD, Madeleine Duvic, MD
9:45 a.m. – 9:50 a.m.	<i>Is mycosis fungoides an antigen driven process? Role of staph aureus and other microorganisms:</i> Joan Guitart, MD
9:50 a.m. – 10:00 a.m.	Panel Discussion: Joan Guitart, MD (facilitator), Youn Kim, MD, Eric Vonderheid, MD, Maarten Vermeer, MD, PhD, Madeleine Duvic, MD

Thursday continued

- 10:00 a.m. – 10:15 a.m. Coffee Break, Poster Viewing, and Exhibits (in the atrium area)
- PART 2: Lymphomagenesis, Genomics, epigenomics and gene Expression**
Session Chairs: Sean Whittaker, MD / Ramon Pujol, MD / Lars French, MD / Gary Wood, MD
- 10:15 a.m. – 10:30 a.m. *What have we learned from molecular technology?* Sean Whittaker, MD
- 10:30 a.m. – 10:45 a.m. **Presenting Author: Michael Girardi, MD; Abstract #21**
IDENTIFYING NEW VENUES FOR THERAPEUTIC INTERVENTION IN CUTANEOUS T-CELL LYMPHOMA VIA HIGH-RESOLUTION CHARACTERIZATION OF THE CTCL GENOME
Lin WM,¹ Carlson K,¹ Reddy S,¹ Thornberg A,² Saksena G,³ Westman S,² Getz G,³ Mane S,² Berger CL,¹ Edelson RL,¹ Girardi M.¹, ¹Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA,² Keck Foundation, New Haven, CT, USA, ³ Broad Institute, Cambridge, MA, USA
- 10:45 a.m. – 11:00 a.m. **Presenting Author: Christine Jones, PhD Student; Abstract #29**
T-PLASTIN EXPRESSION IN SÉZARY SYNDROME: EVIDENCE FOR IMMUNOPHENOTYPIC HETEROGENEITY
Jones-CL, Ferreira-S, Tosi-I, McKenzie-RC, Caesar-JA, Bagot M, Whittaker-SJ, Mitchell-TJ, St Johns Institute of Dermatology, Kings College London, UK Dept of Dermatology, Hôpital Henri Mondor, Créteil, France
- 11:00 a.m. – 11:15 a.m. **Presenting Author: Lars French, Pr.; Abstract #20**
RESISTANCE TO FasL AND TRAIL-MEDIATED APOPTOSIS IN SÉZARY'S SYNDROME T-CELLS IS ASSOCIATED WITH IMPAIRED DEATH RECEPTOR AND cFLIP EXPRESSION
Contassot E¹, Kerl K¹, Jankovic D¹, Roques S^{2,3}, Shane R⁴, Gaide O^{2,3}, Rook AH⁴, French LE¹, ¹Department of Dermatology, Zürich University Hospital, Zürich, Switzerland, ²Department of Pathology and Immunology, University Medical Center, Geneva, Switzerland, ³Department of Dermatology, University Hospital, Geneva, Switzerland, ⁴Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, USA
- 11:15 a.m. – 11:25 a.m. **Presenting Author: Minakshi Nihal, PhD; Abstract #39**
DOWN REGULATION OF POLO-LIKE KINASE-1 IN CUTANEOUS T-CELL LYMPHOMAS CAUSES MITOTIC IRREGULARITIES AND APOPTOSIS
Nihal-M^{1,2}, Stutz-N¹ and Wood-G.S.^{1,2,3}, Department of Dermatology, University of Wisconsin, School of Medicine and Public Health¹ and Paul P. Carbone Comprehensive Cancer Center², Wm. S. Middleton VA Medical centre³, Madison, Wisconsin, USA
- 11:25 a.m. – 11:35 a.m. **Presenting Author: Nathalie Stutz, MD; Abstract #47**
EXPRESSION OF POLO-LIKE KINASE 1 IN CUTANEOUS T-CELL LYMPHOMA
Stutz-N¹, Nihal-M^{1,2}, Wood-GS^{1,2,3}, Department of Dermatology, University of Wisconsin School of Medicine and Public Health¹ and Paul P. Carbone Comprehensive Cancer Center², Wm. S. Middleton VA Medical Centre³, Madison, Wisconsin, USA
- 11:35 a.m. – 11:45 a.m. *Apoptotic abnormalities in MF/SS:* Gary Wood, MD (and review of Abstract #22)
- 11:45 a.m. – 12:00 p.m. Panel Discussion: Gary Wood, MD (facilitator), Sean Whittaker, MD, Ramon Pujol, MD, Lars French, MD
- 12:00 p.m. – 1:00 p.m. Lunch, Poster Viewing, and Exhibits (in the atrium area)

Thursday continued

Session 2: Immunology: T-cell Signaling Dysregulation (immunology, host response, microenvironment, model systems, including pre-clinical models, cell lines, 3-D, tissue models, and animal models)

PART 1:

Session Chairs: Thomas Kupper, MD / Michael Girardi, MD / Sam Hwang, MD, PhD / Martine Bagot, MD, PhD

- 1:00 p.m. – 1:20 p.m. *What we have learned about immune abnormalities in MF/SS:* Thomas Kupper, MD
- 1:20 p.m. – 1:30 p.m. **Presenting Author: Robert McKenzie, PhD Student; Abstract #46**
ABERRANT ACTIVATION OF STAT3 IS INDEPENDENT OF SHP-1 IN PRIMARY SÉZARY CELLS
McKenzie-RCT, Jones-CL, Tosi-I, Ferreira-S, Caesar-JA, Whittaker-SJ, Mitchell-TJ, St John's Institute of Dermatology, Kings College London, UK
- 1:30 p.m. – 1:40 p.m. **Presenting Author: Robert McKenzie, PhD Student; Abstract #45**
EVALUATION OF HISTONE DEACETYLASE INHIBITORS ON THE JAK-STAT3 PATHWAY IN SÉZARY SYNDROME
McKenzie-RCT, Jones-CL, Tosi-I, Ferreira-S, Caesar-JA, Whittaker-SJ, Mitchell-TJ, St John's Institute of Dermatology, Kings College London, UK
- 1:40 p.m. – 1:50 p.m. **Presenting Author: Maarten Vermeer, MD PhD; Abstract #43**
A PATHOLOGICAL ROLE FOR THE IL-21 – STAT3 AXIS IN SÉZARY SYNDROME
Vermeer-MH¹, Out-JJ¹, van Leeuwen-MA², Smit-F¹, Samsom-JN², Willemze-R¹, Tensen-CP¹ and van der Fits-L¹
¹Dept of Dermatology, Leiden University Medical Center, Leiden, the Netherlands, ²Dept of Pediatric Gastroenterology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 1:50 p.m. – 2:00 p.m. Discussion/Questions: Michael Girardi, MD (facilitator)
- 2:00 p.m. – 2:10 p.m. **Presenting Author: Sara Samimi, MD; Abstract #98**
INCREASED PROGRAMMED DEATH 1 EXPRESSION ON CD4+ T-CELLS IN CUTANEOUS T-CELL LYMPHOMA
Samimi SS¹, Benoit BM¹, Wherry EJ², Showe LC³, Evans KG¹, Wysocka M¹, Rook AH¹
1 Department of Dermatology, 2 Department of Microbiology, 3 Department of Molecular and Cellular Oncogenesis, from the University of Pennsylvania School of Medicine and the Wistar Institute, Philadelphia, PA, USA
- 2:10 p.m. – 2:20 p.m. **Presenting Author: Kanchan Kantekure, MD; Abstract #38**
DIFFERENTIAL EXPRESSION OF PD-1/CD279, PD-L1/CD274, AND FOXP3 AT VARIOUS STAGES OF CUTANEOUS T-CELL LYMPHOMA (CTCL)/MYCOSIS FUNGOIDES (MF)
Kantekure-K, Yang-Y, Raghunath-P, Wang-HY, Schaffer-A, Witkiewicz-A, Zhang-Q, Wasik-MA. University of Pennsylvania and Jefferson University, Philadelphia, USA
- 2:20 p.m. – 2:30 p.m. **Presenting Author: Heather Gibson; Abstract #26**
ALTERED PROTEASOME FUNCTION LEADS TO A GATA3-DEPENDENT INCREASE IN CTLA-4, A MECHANISM THAT MAY PROVIDE INSIGHT TO CTLA-4 REGULATION IN CTCL
Gibson H, Marcucci G, Porcu-P, Wong-HK Ohio State University, Columbus, Ohio, USA,¹Division of Hematology, Comprehensive Cancer Center Ohio State University, Columbus, Ohio,²Division of Dermatology, Ohio State University, Columbus, Ohio, USA
- 2:30 p.m. – 2:40 p.m. **Presenting Author: Makoto Sugaya, MD, PhD; Abstract #36**
DIFFERENTIAL PATTERNS OF CXCR3, CCR3, AND CCR10 EXPRESSION IN MYCOSIS FUNGOIDES, SEZARY SYNDROME AND CD30+ LYMPHOPROLIFERATIVE DISORDERS
Sugaya-M, Suga-H, Miyagaki-T, Ohmatsu-H, Sato-S, Department of Dermatology, University of Tokyo, Tokyo, Japan
- 2:40 p.m. – 2:55 p.m. Discussion/Questions: Sam Hwang, MD, PhD (facilitator)
- 2:55 p.m. – 3:05 p.m. *Are Sezary syndrome and mycosis fungoides different diseases?* Maarten Vermeer, MD, PhD
- 3:05 p.m. – 3:10 p.m. Panel Discussion: Maarten Vermeer, MD, PhD (facilitator), Thomas Kupper, MD, Michael Girardi, MD, Sam Hwang, MD, PhD, Martine Bagot, MD, PhD
- 3:10 p.m. – 3:30 p.m. Coffee Break, Poster Viewing, and Exhibits (in the atrium area)

Thursday continued

PART 2:

Session Chairs: Alain Rook, MD / Richard Edelson, MD / Larisa Geskin, MD

3:30 p.m. – 3:45 pm

Presenting Author: Martine Bagot, MD, PhD; Abstract #200

EXPRESSION OF NK RECEPTORS BY CUTANEOUS T-CELL LYMPHOMAS. A NEW HOPE FOR TARGETED THERAPIES

M. Bagot, A. Marie-Cardine, A. Bensussan. Department of Dermatology and Onco-Dermatology Unit, Inserm U976, Skin Research Center, Hôpital Saint Louis, Paris, France

3:45 p.m. – 4:00 p.m.

Presenting Author: Xuesong Wu, MD, PhD; Abstract #48

2,4-DINITROFLUOROBENZENE PROMOTES THE DEVELOPMENT OF A HIGH-GRADE CUTANEOUS T CELL LYMPHOMA BY MBL2 CELLS IN MICE

Wu-XS, Sells-RE, Hwang-ST, Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

4:00 p.m. – 4:15 p.m.

Presenting Author: Oleg Akilov, MD, PhD ; Abstract #24

UPREGULATION OF THE IMMEDIATE EARLY RESPONSE GENE (IEX-1) CORRELATES WITH THE SURVIVAL ADVANTAGE OF MALIGNANT T LYMPHOCYTES IN SÉZARY SYNDROME

Akilov-OE¹, Ustyugova-IV², Wu-MX², Geskin-LJ¹, ¹Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; ²Department of Dermatology, Harvard Medical School, Boston, MA, USA

4:15 p.m. – 5:30 p.m.

Reports of current cooperative efforts from the CLF, ISCL, EORTC, and USCLC

Panel: Gary Wood, MD (ISCL), Elise Olsen, MD (USCLC), Martine Bagot, MD, PhD (EORTC), Judy Jones (CLF)

Consensus statement on trials design & response criteria: Elise Olsen, MD (15-20 min)

Other groups to follow with any updates/reports/announcements

5:30 p.m. – 6:30 p.m.

Welcome Reception and Poster Viewing (in the atrium)

7:00 p.m. – 9:00 p.m.

Session Chair & Organizing Committee Dinner (by invitation only)



First World Congress of Cutaneous Lymphomas

Friday, September 24, 2010

Cutaneous T-Cell Lymphomas (MF/SS): Therapies

7:00 a.m. – 8:30 a.m. **USCLC Board Member Meeting** (Location: Avenue Crown Plaza Hotel, 160 E Huron, 5th Avenue Room)
By Invitation Only.

Session 3: Clinical Trials and Management with Novel Targets and Agents

8:15 a.m. – 9:00 a.m. Breakfast (atrium)

Note: Later Start Time

PART 1: Clinical Trials Design and New/Novel Skin-Directed Therapies

Session Chairs: Elise Olsen, MD / Stuart Lessin, MD / Reinhard Dummer, MD / Nicola Pimpinelli, MD

9:00 a.m. – 9:05 a.m. *Introduction and overview of Friday's program:* Youn Kim, MD

9:05 a.m. – 9:15 a.m. **Presenting Author: Sean Whittaker, MD; Abstract #50**

CUTANEOUS LYMPHOMA PROGNOSTIC INDEX (CLPI)

EC Benton, S Crichton, NS Agar, P Fields, E Wedgeworth, TJ Mitchell, M Cox, S Ferreira, A Robson, E Calonje, CM Stefanato, EM Wain, B Wilkins, P Fields, K Webb, J Scarisbrick, S Morris, SJ Whittaker St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London and Division of Genetics and Molecular Medicine, Kings College London, UK

9:15 a.m. – 9:25 a.m. **Presenting Author: Kamel Belkacem-Boussaid, Ph.D; Abstract #37**

COMPUTER-ASSISTED IDENTIFICATION OF BOUNDARIES OF LESIONS IN CUTANEOUS LYMPHOMAS

Boussaid-BK¹, Porcu-P², Wong-HK^{2,3}, Gurcan-MN¹, ¹Department of Biomedical Informatics, Ohio State University, Columbus, Ohio, USA, ²Division of Hematology, Comprehensive Cancer Center Ohio State University, Columbus, Ohio, ³Division of Dermatology, Ohio State University, Columbus, Ohio, USA

9:25 a.m. – 9:35 a.m. Discussion/Questions: Stuart Lessin, MD (facilitator)

9:35 a.m. – 9:45 a.m. **Presenting Author: Stuart R. Lessin, MD; Abstract #49**

A RANDOMIZED, PIVOTAL TRIAL TO EVALUATE THE SAFETY & EFFICACY OF 0.02% NITROGEN MUSTARD (NM) FORMULATIONS IN PATIENTS WITH STAGE I OR IIA MYCOSIS FUNGOIDES (MF)

Lessin-SR¹, Duvic-M², Guitart-J³, Pandya-A⁴, Strober-BE⁵, Olsen-EA⁶, Hull-CM⁷, Knobler-EH⁸, Rook-AH⁹, Kim-EJ⁹, Naylor-MF¹⁰, Adelson-DM¹⁰, Kimball-AB¹¹, Wood-GS¹², Wu-H¹, Walker-BR¹³, Kim-YH¹⁴. ¹Fox Chase Cancer Center, Phila, PA; ²MD Anderson Cancer Center, Houston, Tx; ³Northwestern Univ, Chicago, IL; ⁵New York Univ, NYC, NY; ⁶Duke Univ, Durham, NC; ⁷Univ of Utah, SLC, UT; ⁸Columbia Univ, NYC, NY; ⁹Univ of PA, Phila PA; ¹⁰Univ of Oklahoma, Oklahoma City, OK; ¹¹Harvard Univ, Boston, MA; ¹²Univ of Wisconsin, Madison, WI; ¹³Yaupon Therapeutics, Radnor, PA; ¹⁴Stanford Univ, Palo Alto, CA., USA

9:45 a.m. – 9:55 a.m. **Presenting Author: James Bradner, MD; Abstract #72**

SHP-141: A NOVEL, TOPICAL, REVERSE PRO-DRUG HISTONE DEACETYLASE INHIBITOR FOR THE MANAGEMENT OF INDOLENT CUTANEOUS T-CELL LYMPHOMA

Chappell T, Ponduru S, Rich B, Landau SB, Mazitschek R, Bradner JE, Shape Pharmaceuticals, Cambridge MA, USA

9:55 a.m. – 10:05 a.m. **Presenting Author: Cameron Harrison, MD; Abstract #52**

A PHASE II STUDY OF LOW-DOSE (12 Gy) TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES

Harrison C¹, Kim Y¹, Navi D¹, Armstrong R², Weng W², and Hoppe R³, Departments of ¹Dermatology, ²Medicine, and ³Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

10:05 a.m. – 10:15 a.m. Panel Discussion: Reinhard Dummer, MD (facilitator), Elise Olsen, MD, Stuart Lessin, MD, Nicola Pimpinelli, MD

Friday continued

10:15 a.m. – 10:30 a.m. Coffee Break, Poster Viewing, and Exhibits (in the atrium area)

PART 2: New/Novel Targets and Systemic Therapies

Session Chairs: Timothy Kuzel, MD / Alain Rook, MD / Francine Foss, MD / Mark Pittelkow, MD

10:30 a.m. – 10:40 a.m. *How are we doing with development of new therapies?* Timothy Kuzel, MD

10:40 a.m. – 10:52 a.m. **Presenting Author: Mariusz Wasik MD; Abstract #75**

COMBINED INHIBITION OF mTOR-CONTAINING COMPLEX 1 (mTORC1) AND MNK KINASE INDUCES APOPTOSIS OF CUTANEOUS T-CELL LYMPHOMA (CTCL) CELLS

Marzec-M, Liu-X, Wasik-MA. University of Pennsylvania, Philadelphia, USA

10:52 a.m. – 11:04 a.m. **Presenting Author: Madeleine Duvic, MD; Abstract #77**

KW-0761, A MONOCLONAL ANTIBODY DIRECTED AGAINST CC CHEMOKINE RECEPTOR TYPE 4 (CCR4), IN PTCL AND CTCL PATIENTS: ANTIGEN EXPRESSION MAY CORRESPOND TO HIGHER LIKELIHOOD OF CLINICAL RESPONSE

Duvic M,¹ Jorgensen J,² Ni X,¹ Abdulla F,³ Talpur R,¹ Reddy S,⁴ Daulat S,¹ Spitalny G,⁵ and Kim Y,³
Departments of ¹Dermatology and ²Hematopathology, UT MD Anderson Cancer Center; Departments of ³Dermatology and ⁴Medicine (Division of Medical Oncology), Stanford Cancer Center; ⁵Kyowa Hakko Kirin Pharma, Inc.

11:04 a.m. – 11:16 a.m. **Presenting Author: Larisa Geskin, MD; Abstract #73**

PATIENT-SPECIFIC DENDRITIC CELL IMMUNIZATION AGAINST TUMOR IN SÉZARY SYNDROME

Geskin-LJ, Akilov-OE, Butterfield-L, Whiteside-TL, Faló-LD, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA

11:16 a.m. – 11:28 a.m. **Presenting Author: Youn Kim, MD; Abstract #78**

IN SITU VACCINATION WITH TLR9 AGONIST COMBINED WITH LOCAL RADIATION IN MYCOSIS FUNGOIDES: FINAL ANALYSIS

Kim Y,¹ Gratzinger D,² Harrison C,¹ Brody J,³ Xing L,¹ Czerwinski D,³ Morales A,¹ Ai W,³ Abdulla F,¹ Navi D,¹ Tibshirani R,⁴ Advani R,³ Natkunam Y,² Hoppe R,⁵ and Levy R,³
Departments of ¹Dermatology, ²Pathology, ³Medicine, ⁴Health Research & Policy, ⁵Radiation Oncology, Stanford University School of Medicine, Stanford CA, USA

11:28 a.m. – 11:40 a.m. **Presenting Author: Alain Rook, MD; Abstract #79**

SYNERGISTIC ENHANCEMENT OF CELL-MEDIATED IMMUNITY WITH A NOVEL TOLL-LIKE RECEPTOR AGONIST AND INTERFERON GAMMA OR IL-15

Alain H. Rook, Andrea B. Troxel, Bernice M. Benoit, Amy C. Musiek, Sara S. Samimi, Ellen J. Kim, Louise C. Showe, Joel M. Gelfand, Maria Wysocka. University of Pennsylvania, Philadelphia, PA, USA

11:40 a.m. – 11:50 a.m. Panel Discussion: Alain Rook, MD (facilitator), Timothy Kuzel, MD, Francine Foss, MD, Mark Pittelkow, MD

11:50 a.m. – 1:00 p.m. Lunch, Poster Viewing, and Exhibits (in the atrium area)

11:50 a.m. – 1:00 p.m. **USCLC General Membership Meeting (Main Conference Room during lunch).**

Friday continued

Session 4: Clinical Trials and Management with Available Therapies

PART 1:

Session Chairs: Steven Horwitz, MD / Youn Kim, MD / Teresa Estrach, MD / Pablo Ortiz-Romero, MD, PhD

:00 p.m. – 1:05 p.m.	<i>Introduction of afternoon session: Choices and decisions on systemic therapies:</i> Youn Kim, MD
1:05 p.m. – 1:20 p.m.	(Presenting Author: <u>Christiane Querfeld, MD, PhD; Abstract #63</u> EVALUATION OF A PHASE II MULTICENTER TRIAL OF LENALIDOMIDE IN PATIENTS WITH RELAPSED CUTANEOUS T-CELL LYMPHOMA <u>Querfeld-C</u> ¹ , <u>Rosen-ST</u> ² , <u>Joan Guitart-J</u> ¹ , <u>Duvic-M</u> ³ , <u>Kim-YH</u> ⁴ , <u>Kuzel-TM</u> ² . ¹ Dept of Dermatology and ² Dept of Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, ³ Dept of Dermatology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, ⁴ Dept of Dermatology, Stanford Cancer Center, Stanford, CA, USA
1:20 p.m. – 1:35 p.m.	Presenting Author: <u>Steven Horwitz, MD; Abstract #55</u> PRALATREXATE IN RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL): RESULTS OF THE PDX-010 DOSE-FINDING TRIAL <u>Horwitz, S</u> ¹ ; <u>Duvic, M</u> ² ; <u>Kim, Y</u> ³ ; <u>Myskowski, P</u> ¹ ; <u>Zain, J</u> ⁴ ; <u>Lechowicz, MJ</u> ⁵ ; <u>Koutsoukos, Y</u> ⁶ ; <u>Fruchtman, S</u> ⁶ ; <u>O'Connor, O</u> ⁴ , 1Memorial Sloan-Kettering Cancer Center, New York, NY; 2University of Texas MD Anderson Cancer Center, Houston, TX; 3Stanford Cancer Center, Stanford, CA; 4New York University Cancer Institute, NYU Langone Medical Center, New York, NY; 5Emory, Atlanta, GA, 6Allos Therapeutics
1:35 p.m. – 1:50 p.m.	Presenting Author: <u>Pietro Quaglino, MD; Abstract #60</u> TREATMENT OF SEZARY SYNDROME BY ANTI-CD52 MONOCLONAL ANTIBODY ALEMTUZUMAB: CLINICAL AND IMMUNOLOGICAL FINDINGS IN 24 PATIENTS <u>Bernengo-MG</u> , <u>Quaglino-P</u> , <u>Marenco-F</u> , <u>Novelli-M</u> , <u>Comessatti-A</u> , <u>Savoia-P</u> , <u>Fierro-MT</u> . Department of Biomedical Sciences and Human Oncology, Dermatologic Clinic, University of Turin, Italy
1:50 p.m. – 2:00 p.m.	<i>HDAC-I rational strategy for combination therapy:</i> Steven Horwitz, MD
2:00 p.m. – 2:10 p.m.	Presenting Author: <u>Aleksandra Anshelevich, BS; Abstract #65</u> MINIMIZING THE IMMUNOSUPPRESSIVE EFFECTS OF HISTONE DEACETYLASE INHIBITORS (HDACI): IMPLICATIONS FOR THERAPY OF CUTANEOUS T-CELL LYMPHOMA (CTCL) <u>Anshelevich A</u> , <u>Wysocka M</u> , <u>Benoit BM</u> , <u>Rook AH</u> , Department of Dermatology, University of Pennsylvania, Philadelphia, USA
2:10 p.m. – 2:20 p.m.	Presenting Author: <u>Maria Karpova, PhD; Abstract #68</u> MOLECULAR ADAPTATION IN ADVANCED CUTANEOUS T-CELL LYMPHOMA CAUSED BY VORINOSTAT/BEXAROTENE THERAPY <u>Karpova MB</u> , <u>Gunz D</u> ¹ , <u>Belloni B</u> , <u>Okoniewski MJ</u> ² , <u>Cozzio A</u> , <u>Schad K</u> , <u>Baumann-Conzett K</u> , <u>French LE</u> , <u>Dummer R</u> ; Department of Dermatology, University Hospital, Zurich, Switzerland; ¹ - Merck, Sharp & Dohme Corp., Opfikon-Glattbrugg, Switzerland; ² - Functional Genomics Center, University of Zürich, Zurich, Switzerland
2:20 p.m. – 2:30 p.m.	Presenting Author: <u>Chunlei Zhang, MD, PhD; Abstract #61</u> MOLECULAR AND BIOLOGIC CHARACTERIZATION OF VORINOSTAT-RESISTANT CUTANEOUS T-CELL LYMPHOMA CELLS: POTENTIAL ROLE FOR RANK/NF-κB SIGNALING <u>Zhang-CL</u> , <u>Zhang-X</u> , <u>Li-BQ</u> , <u>Duvic-M</u> , Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
2:30 p.m. – 2:45 p.m.	Panel Discussion (HDAC-I and combination strategy) Steven Horwitz, MD (facilitator), Youn Kim, MD, Teresa Estrach, MD, Pablo Ortiz-Romero, MD, PhD
2:45 p.m. – 3:00 p.m.	Coffee Break, Poster Viewing, and Exhibits (in the atrium area)

Friday continued

PART 2:

Session Chairs: Madeleine Duvic, MD / Pier Luigi Zinzani, MD, PhD / Robert Knobler, MD / John Zic, MD

- 3:00 p.m. – 3:10 p.m. *What we know now about photopheresis:* Richard Edelson, MD
- 3:10 p.m. – 3:20 p.m. **Presenting Author: Tyler Durazzo; Abstract #66**
MECHANISM UNDERLYING EXTRACORPOREAL PHOTOCHEMOTHERAPY'S EFFICIENT AND RAPID INDUCTION OF MONOCYTE-TO-DENDRITIC CELL MATURATION
Durazzo TS¹, Berger CL¹, Girardi M¹, Foss FM¹, Tigelaar RE¹, Edelson RL¹, ¹Department of Dermatology and Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA
- 3:20 p.m. – 3:30 p.m. **Presenting Author: Brian Raphael, BA; Abstract #70**
HIGH CLINICAL RESPONSE RATE OF SÉZARY SYNDROME WITH IMMUNE MODIFYING THERAPIES: PROGNOSTIC MARKERS OF RESPONSE
Raphael BA, Shin DB, Suchin KR, Morrissey KA, Vittorio CC, Kim EJ, Gardner JM, Evans KG, Introcaso CE, Gelfand JM, Rook AH, Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
- 3:30 p.m. – 3:40 p.m. **Presenting Author: Madeleine Duvic, MD; Abstract #62**
MULTICENTER PHOTOPHERESIS INTERVENTION TRIAL IN EARLY STAGE MYCOSIS FUNGOIDES
Duvic-M, Talpur-R, Geskin-L, Baron-E, Pugliese-S, Eubank-K, Zic-JA, Miller-DR, Tharp -M, Bohjanen-K, Demierre-MF* Departments of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, Boston Medical Center, Boston, Massachusetts, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, Case Western Reserve, Cleveland, Ohio, Vanderbilt University Medical Center, Nashville, Tenn, Rush Medical Center, Chicago, Illinois, and University of Minnesota, St Paul, Minnesota, USA
- 3:40 p.m. – 3:50 p.m. Discussion/Questions: Robert Knobler, MD (facilitator), Madeleine Duvic, MD, Richard Edelson, MD, Pier Luigi Zinzani, MD, PhD, John Zic, MD
- 3:50 p.m. – 4:05 p.m. HSCT in MF/SS Discussion Session: *HSCT in MF/SS:* PierLuigi Porcu, MD
- 4:05 p.m. – 4:15 p.m. **Presenting Author: Francesco Onida, MD; Abstract #56**
REDUCED-INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADVANCED STAGE MYCOSIS FUNGOIDES AND SÉZARY SYNDROME
Onida-F^{1,2}, Berti-E^{3,4}, Saporiti-G^{1,2}, Annaloro-C¹, Corti-L^{1,2}, Vezzoli-P³, Usardi-P¹, Olivares-C¹, Tagliaferri-E¹, Lambertenghi Delilieri-G^{1,2}, ¹Bone Marrow Transplantation Center- Hematology 1, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milan, Italy; ²Fondazione Matarrelli per lo Studio e la Cura delle Malattie del Sangue, Milan, Italy; ³Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁴University of Milan-Bicocca, Milan, Italy
- 4:15 p.m. – 4:25 p.m. *Which CTCL patients should be considered for HSCT & when is the right time?* Madeleine Duvic, MD
- 4:25 p.m. – 4:35 p.m. *What regimen?* Jayesh Mehta, MD
- 4:35 p.m. – 4:40 p.m. Panel Discussion: PierLuigi Porcu, MD (facilitator), Madeleine Duvic, MD, Pier Luigi Zinzani, MD, PhD, Robert Knobler, MD, John Zic, MD
- 4:40 p.m. – 5:15 p.m. **Future Direction and Cooperative Investigation in Cutaneous Lymphoma**
Sean Whittaker, MD (moderator), Gary Wood, MD, Elise Olsen, MD, Martine Bagot, MD, PhD
- 6:00 p.m. **Trolleys depart from Avenue Crown Plaza Hotel (corner of Huron & St. Clair) for All-Attendee Dinner**
- 6:30 p.m. – 9:00 p.m. **Dinner Banquet in honor of Dr. Eric Vonderheid at the Chicago History Museum**
Included with your registration
- 9:00 p.m. **Trolleys Pick Up and Return to Hotels**



First World Congress of Cutaneous Lymphomas

Saturday, September 25, 2010

7:00 – 8:00 a.m.

ISCL Board Meeting (Location: Feinberg Pavilion, Conference Room E)
By Invitation Only.

Session 5: Other Cutaneous T-cell Lymphomas

7:15 a.m. – 8:00 a.m.

Breakfast (atrium)

8:00 a.m. – 8:25 a.m.

PART1: CD 30+ Lymphoproliferative disorders

Session Chairs: Lauren Pinter-Brown, MD / Werner Kempf, MD / Marshall Kadin, MD / Ellen Kim, MD

Overview of CD30 lymphoproliferative disorders and abstracts: Marshall Kadin, MD

Presenting Author: Marshall Kadin, MD; Abstract #42

LYMPHOMATOID PAPULOSIS: CLINICAL FEATURES FROM A UNITED STATES CASE REGISTRY

Gomez ML¹, Saboda K³, Kadin ME², Wang H¹, Curiel-Lewandrowski C³

¹Beth Israel Deaconess Medical Center, Departments of Dermatology and Pathology Boston MA; ²Roger Williams Medical Center, Department of Dermatology, Providence, RI; ³Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

Presenting Author: Marshall Kadin, MD; Abstract #93

CD30+ CUTANEOUS ALCL LINES EXPRESS TH17 CYTOKINES AND HARBOR A PCM1-JAK2 FUSION: A MODEL FOR PATHOBIOLOGY AND TREATMENT OF CD30+ CTCL

Marshall Kadin¹, Xiaofeng Lin¹, Bjorn Schneider², Stefan Nagel², Hans Drexler², Eric Vonderheid³, Roderick MacLeod², ¹Boston University and Roger Williams Medical Center, Providence RI, ²DSMZ, Braunschweig, Germany, ³Johns Hopkins Medical Center, Baltimore MD, USA

8:25 a.m. – 8:35 a.m.

Presenting Author: Julia M. Sánchez-Schmidt, MD; Abstract #11

AN OLIGONUCLEOTIDE ARRAYCGH APPROACH OF PRIMARY CUTANEOUS CD30+ ANAPLASTIC LARGE CELL LYMPHOMAS

Sánchez-Schmidt JM¹, Pujol-RM¹, Salgado-R², Gallardo-F¹, Servitje-O³, Climent-F⁴, Ortiz-PL⁵, Karpova-MB⁶, Zipser-MC⁶, Dummer-R⁶, García-MP⁷, Estrach-T⁸, Rodríguez-MS⁹, Ferreira-BI¹⁰, Cigudosa-JC¹⁰, Solé-F², Espinet-B²

¹Dept. of Dermatology and ²Lab. de Citogenética Molecular-Servei de Patologia, IMIM-Parc de Salut Mar, Barcelona; ³Dept. of Dermatology and ⁴Pathology, Hosp. Universitari de Bellvitge. L'Hospitalet de Llobr.; ⁵Dept. of Dermatology, Hosp. 12 de Octubre, Madrid, Spain; ⁶Dept. of Dermatology, University Hospital Zürich. Zürich, Switzerland; ⁷Dept. of Dermatology, Hosp. de Sant Pau and ⁸Hosp. Clínic-IDIBAPS, Barcelona, ⁹Dept. de Patologia Molecular and ¹⁰Grupo de Citogenética Molecular, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

8:35 a.m. – 8:45 a.m.

Presenting Author: Qian Zhang MD, PhD; Abstract #12

DIFFERENTIAL DEGREE OF ICOS EXPRESSION BY CUTANEOUS T-CELL LYMPHOMA (CTCL) AND ANAPLASTIC LYMPHOMA KINASE-EXPRESSING T-CELL LYMPHOMA (ALK+TCL)

Zhang-Q, Wang-HY, Kantekure-K, Paterson-JC, Liu-X, Schaffer-A, Marafioti-T, Wasik-MA. University of Pennsylvania, Philadelphia, USA and University College, London, UK

8:45 a.m. – 9:00 a.m.

Defining lymphomatoid papulosis: Werner Kempf, MD

Panel Discussion: Werner Kempf, MD (facilitator), Lauren Pinter-Brown, MD, Marshall Kadin, MD, Ellen Kim, MD

Saturday continued

9:00 a.m. – 9:10 a.m.	<p>Presenting Author: Werner Kempf, MD, Professor; Abstract #94 MANAGEMENT OF CD30+ LYMPHOPROLIFERATIVE DISORDERS: DATA OF A SYSTEMIC REVIEW AND EORTC CONSENSUS RECOMMENDATIONS W. Kempf, M. H. Vermeer, P. Ortiz, M. Bagot, A. Cozzio, R. Dummer, L.E. French, R. Knobler, R. Willemze on behalf of the EORTC Cutaneous Lymphoma Task Force. Dept. of Dermatology, University Hospital Zürich, Switzerland (presenting author)</p>
9:10 a.m. – 9:25 a.m.	<p>Panel Discussion (Clinical Management): Lauren Pinter-Brown, MD (facilitator), Werner Kempf, MD, Marshall Kadin, MD, Ellen Kim, MD</p>
9:25 a.m. – 9:40 a.m.	<p>Coffee Break, Poster Viewing, and Exhibits (in the atrium area)</p>
9:40 a.m. – 10:00 a.m.	<p>PART 2: Cytotoxic Lymphomas and Other Rare Variants Session Chairs: Joan Guitart, MD / Rudolf Stadler, MD / Emilio Berti, MD / Francine Foss, MD / Lorenzo Cerroni, MD</p> <p><i>Overview of cytotoxic lymphomas - the US experience:</i> Joan Guitart, MD</p> <p>Presenting Author: Joan Guitart, MD; Abstract #92 CUTANEOUS GAMMA-DELTA LYMPHOMAS: THE US EXPERIENCE Guitart J (1), Subtil A (2), Kim E (3), Duvic M (4), Wood G (5), Weisenburger D (6), Olsen E (7), Junkins-Hopkins J (8), Rosen S (1), Sundram U (2), Ivan D (5), Selim A (7), Zwerner J (2), Kim Y (2). Depts of Dermatology, Pathology and/or Internal Medicine, Hem/onc division at (1) Northwestern U Chicago IL, (2) Yale U New Haven CN, (3) U Pennsylvania Philadelphia PA, (4) MD Anderson Houston TX, (5) U Wisconsin WI, (6) U Nebraska NE, (7) Duke U Durham NC, (8) Johns Hopkins U Baltimore MA, USA</p>
10:00 a.m. – 10:25 a.m.	<p><i>Cytotoxic lymphomas the Italian/European experience and abstracts# 19, 90, 85:</i> Emilio Berti, MD</p> <p>Presenting Author: Emilio Berti, MD; Abstract #19 CUTANEOUS T-CELL LYMPHOMAS CD8+ Berti-E, Vezzoli-P, Alberti Violetti-S, Venegoni-L, Fanoni-D, Merlo-V, Crippa-F, Crosti-C U.O. Dermatologia, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche, Università degli Studi di Milano, Milan, Italy</p> <p>Presenting Author: Emilio Berti, MD; Abstract #90 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS IN CD8+ AGGRESSIVE PRIMARY CUTANEOUS EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA Fanoni D¹, Tensen CP², Novara F³, Willemze R², Berti E^{1,4}. ¹U.O. Dermatologia, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche, Università degli Studi di Milano, Milan, Italy. ²Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands. ³Dipartimento di Genetica Medica, University of Pavia, Pavia, Italy. ⁴Department of Clinical Medicine and Prevention, University of Milan-Bicocca, Milan, Italy</p> <p>Presenting Author: Pamela Vezzoli, MD PhD; Abstract #85 CUTANEOUS EXTRANODAL NK/T-CELL LYMPHOMA: A CLINICOPATHOLOGIC STUDY OF 5 PATIENTS WITH ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION Berti E,^{1,2} Recalcati S,² Girgenti V,² Fanoni-D,² Venegoni L,² Fiorani R, Crosti C, Vezzoli P² ¹Department of Clinical Medicine and Prevention, University of Milan-Bicocca, Milan, Italy.; ²U.O. Dermatologia, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche, Università degli Studi di Milano, Milan, Italy</p>
10:25 a.m. – 10:40 a.m.	<p>Discussion/Questions: Joan Guitart, MD (facilitator)</p>
10:40 a.m. – 10:52 a.m.	<p>Presenting Author: Pablo L. Ortiz-Romero, MD, PhD; Abstract #81 HYDROA VACCINIFORME-LIKE LYMPHOMA (HV-L). A SERIES OF 15 CASES FROM PERÚ SM Rodríguez(1), PL Ortiz (2), C Barrionuevo(3), J Garcia(3), R Pajares(1), S Montes(1), L Sanchez(1), MA Piris(1). 1: CNIO, Madrid, Spain. 2: Hospital 12 de Octubre. Madrid, Spain, 3: INEN, Perú</p>
10:52 a.m. – 11:04 a.m.	<p>Presenting Author: Sonja Hahtola, MD, PhD; Abstract #28 SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA SHOWS A MOLECULAR SIGNATURE CHARACTERISTIC FOR AUTOIMMUNE DISEASES Maliniemi-P¹, Hahtola-S¹, Väkevä-L¹, Ovaska-K², Jeskanen-L¹, Stadler-R³, Niiranen-K¹, Hautaniemi-S², Ranki A¹. ¹Department of Dermatology, Helsinki University Hospital, Helsinki, Finland, ²Institute of Biomedicine, University of Helsinki, Finland, ³Department of Dermatology, Medical Centre Minden, Minden, Germany</p>

Saturday continued

11:04 a.m. – 11:16 a.m.	<p>Presenting Author: Giacomo Fiandrino, MD; Abstract #91 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM: CLINICOPATHOLOGIC AND COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS OF 21 CASES Paulli-M¹, Lucioni-M¹, Novara-F¹, <u>Fiandrino-G¹</u>, Riboni-R¹, Fanoni-D², Guanziroli-E², Venegoni-L², Nicola-M¹, Borroni-G¹, Zuffardi-O¹, Berti-E² ¹ Human and Hereditary Pathology Department, University of Pavia/IRCCS Policlinico San Matteo, Pavia, Italy ² Dermatology, Bicocca University/IRCCS Ospedale Maggiore, Milan, Italy</p>
11:16 a.m. – 11:30 a.m.	Panel discussion: Francine Foss, MD (facilitator), Joan Guitart, MD, Lorenzo Cerroni, MD, Rudolf Stadler, MD, Emilio Berti, MD
11:30 a.m. – 12:15 p.m.	Lunch, Poster Viewing, and Exhibits (in the atrium area)
11:30 a.m. – 12:15 p.m.	ISCL General Membership & Business Meeting (Main Conference Room during lunch).

Session 6: Cutaneous B-Cell Lymphomas

	<p>Cutaneous B-Cell Lymphomas Session Chairs: Lorenzo Cerroni, MD / Youn Kim, MD / Liisa Väkevä, MD, PhD</p>
12:15 p.m. – 12:35 p.m.	PCBCL overview: Classification/ontogeny, pathomechanisms, etiology (and Abstract #201) Lorenzo Cerroni, MD
12:35 p.m. – 12:45 p.m.	<p>Presenting Author: Anjali Morales, MD, PhD; Abstracts #8 and #9 UTILITY OF COMBINED IGH AND IGK BIOMED-2 CLONALITY ASSAYS TO DISTINGUISH PRIMARY CUTANEOUS B CELL LYMPHOMA FROM CUTANEOUS LYMPHOID HYPERPLASIA AND ASSESS CLONAL IDENTITY AT DIFFERENT SITES OR TIME POINTS <u>Morales-AV¹</u>, Fujiwara-M², Seo-K², Arber-DA², Kohler-S^{1,2}, Kim-YH¹, Sundram-UN^{1,2}, (1) Department of Dermatology, (2) Department of Pathology, Stanford University Medical Center, Stanford, CA USA</p> <p>COMPARISON OF IN SITU HYBRIDIZATION AND IMMUNOHISTOCHEMISTRY IN DETECTING LIGHT CHAIN RESTRICTION IN CUTANEOUS B-CELL LYMPHOMA Khodosh-R¹, <u>Morales-AV¹</u>, Kim-YH¹, Sundram-UN^{1,2}, (1) Department of Dermatology, (2) Department of Pathology, Stanford University Medical Center, Stanford, CA, USA</p>
12:45 p.m. – 12:55 p.m.	<p>Presenting Author: Kanchan Kantekure, MD; Abstract #3 FLOW CYTOMETRY IN THE DIAGNOSIS OF CUTANEOUS LYMPHOID LESIONS <u>Kantekure-K</u>, Al-Saleem-T, Lessin-SR, Wu-H. Fox Chase Cancer Center, Phila, PA, USA</p>
12:55 p.m. – 1:05 p.m.	<p>Presenting Author: Octavio Servitje, MD, PhD; Abstract #2 PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG-TYPE AND TESTICULAR LYMPHOMA. TWO RELATED ENTITIES? <u>Servitje-O^a</u>, Pujol-RM^b, Muniesa-C^c, Gallardo-F^b, Garcia Muret-MP^d, Climent-J^e, Estrach-T^f. Departments of Dermatology, ^aHospital Universitari de Bellvitge, ^bHospital del Mar, ^cHospital de Viladecans, ^dHospital de Sant Pau, ^eHospital Clinic, and ^fDepartment of Pathology, Hospital Universitari de Bellvitge. Barcelona. Spain</p>
1:05 p.m. – 1:15 p.m.	Discussion/Questions: Lorenzo Cerroni, MD
1:15 p.m. – 1:30 p.m.	Focused discussion on clinical management including role of rituximab: Lorenzo Cerroni, MD, Youn Kim, MD, Liisa Väkevä, MD, PhD
1:30 p.m. – 1:45 p.m.	Coffee Break, Poster Viewing, and Exhibits (in the atrium area)

Saturday continued

Session 7: Quality of Life Issues, Patient Education, and Support

1:45 p.m. – 2:10 p.m.	<p>Quality of Life Issues, Patient Education & Support Session Chairs: Suephy Chen, MD / Judy Jones / Lynne Wagner, PhD / Elise Olsen, MD</p> <p><i>Overview of QOL in CTCL & abstracts # 101, 102, 103:</i> Suephy Chen, MD</p> <p>Presenting Author: Suephy Chen, MD; Abstract #101 PRURITUS IN CUTANEOUS T-CELL LYMPHOMA PATIENTS: PREVALENCE AND QUALITY OF LIFE IMPACT Chen-SC^{1,2}, Nguyen-L³, Pugliese-S⁴, Al-Dawsari-N⁴, Demierre-MF⁴, Linos-E⁵, Kim-Y⁵, Parker-SS¹, ¹Department of Dermatology, Emory University, Atlanta, GA; ²Atlanta Veterans Affairs Medical Center, Atlanta, GA; ³School of Medicine, University of Sint Eustatius, Sint Eustatius, Netherlands-Antilles Dutch Caribbean; ⁴Department of Dermatology, Boston University, Boston, MA; ⁵Department of Dermatology, Stanford University, Stanford, CA, USA</p> <p>Presenting Author: Suephy Chen, MD; Abstract #102 QUALITY OF LIFE IMPACT BY CUTANEOUS T-CELL LYMPHOMA: CURRENT INSTRUMENTS MAY NOT BE SUFFICIENT Chen-SC^{1,2}, Nguyen-L³, Pugliese-S⁴, Al-Dawsari-N⁴, Sahn-RE¹, Linos-E⁵, Kim-Y⁵, Parker-SS¹, Demierre-MF⁴, ¹Department of Dermatology, Emory University, Atlanta, GA; ²Atlanta Veterans Affairs Medical Center, Atlanta, GA; ³School of Medicine, University of Sint Eustatius, Sint Eustatius, Netherlands-Antilles Dutch Caribbean; ⁴Department of Dermatology, Boston University, Boston, MA; ⁵Department of Dermatology, Stanford University, Stanford, CA, USA</p> <p>Presenting Author: Suephy Chen, MD; Abstract #103 QUALITY OF LIFE IMPACT BY CUTANEOUS T-CELL LYMPHOMA: RESULTS FROM EXISTING INSTRUMENTS Chen-SC^{1,2}, Nguyen-L³, Pugliese-S⁴, Al-Dawsari-N⁴, Sahn-RE¹, Linos-E⁵, Kim-Y⁵, Parker-SS¹, Demierre-MF⁴, ¹Department of Dermatology, Emory University, Atlanta, GA; ²Atlanta Veterans Affairs Medical Center, Atlanta, GA; ³School of Medicine, University of Sint Eustatius, Sint Eustatius, Netherlands-Antilles Dutch Caribbean; ⁴Department of Dermatology, Boston University, Boston, MA; ⁵Department of Dermatology, Stanford University, Stanford, CA, USA</p>
2:10 p.m. – 2:20 p.m.	<p>Presenting Author: Lynne I. Wagner, PhD; Abstract #105 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH CUTANEOUS LYMPHOMA (CTCL): DEVELOPMENT OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY (FACT) - CTCL Wagner LI, Zaluda L, Guitart J, Kuzel T, Querfeld C, Rosen S, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA</p>
2:20 p.m. – 2:30 p.m.	<p>Presenting Author: Alok Vij, BS; Abstract #106 INCIDENCE AND SEVERITY OF PATIENT-REPORTED PRURITUS IN CUTANEOUS T-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS Vij-A, Duvic-M, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA</p>
2:30 p.m. – 2:45 p.m.	<p>Panel Discussion: Lynne Wagner, PhD (facilitator), Suephy Chen, MD, Judy Jones, Elise Olsen, MD</p>
2:45 p.m.	<p>Closing remarks and farewell. Joan Guitart, MD, Youn Kim, MD, Elise Olsen, MD, Gary Wood, MD</p>